Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM. Mayer EL, et al. Among authors: mahtani r. J Clin Oncol. 2024 Mar 21:JCO2301940. doi: 10.1200/JCO.23.01940. Online ahead of print. J Clin Oncol. 2024. PMID: 38513188
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results.
Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. Rugo HS, et al. Among authors: mahtani r. Future Oncol. 2024 Jan;20(1):5-16. doi: 10.2217/fon-2023-0407. Epub 2023 Nov 2. Future Oncol. 2024. PMID: 37916267 Free article. Review.
Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial.
Jagsi R, Barlow WE, Woodward WA, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein SR, Zeidan Y, Zhang H, Sharma P, Pusztai L, Hortobagyi GN, Kalinsky K. Jagsi R, et al. Among authors: mahtani r. JAMA Oncol. 2023 Aug 1;9(8):1083-1089. doi: 10.1001/jamaoncol.2023.1984. JAMA Oncol. 2023. PMID: 37410451 Clinical Trial.
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Mahtani R, et al. BMC Cancer. 2022 Dec 22;22(1):1343. doi: 10.1186/s12885-022-10325-9. BMC Cancer. 2022. PMID: 36550413 Free PMC article.
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. Rugo HS, et al. Among authors: mahtani r. Breast. 2022 Dec;66:324-331. doi: 10.1016/j.breast.2022.11.005. Epub 2022 Nov 15. Breast. 2022. PMID: 36463643 Free PMC article. Clinical Trial.
Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Mahtani R, et al. Breast. 2022 Dec;66:236-244. doi: 10.1016/j.breast.2022.10.009. Epub 2022 Oct 18. Breast. 2022. PMID: 36368161 Free PMC article.
64 results